Big pharma firms have paused nearly £2bn in UK investments this year Government’s plans in disarray before Trump talks as MSD, Eli Lilly and AstraZeneca moves prompt job fears

#lifesciences #biotech #Pharmaceuticals #AstraZeneca #Trump #MSD #EliLilly #drugpricing #ABPI #BristolMyersSquibb #NHS #VPAG #Sanofi #Novartis #BioNTech #Moderna #Haleon #Indivior #VeronaPharma #AdaptimmuneTherapeutics #WorldMeds #GSK #RentschlerBiopharma #Recipharm
zurl.co/3FQOT

Why Verona Pharma’s FDA Win Could Trigger a Billion-Dollar Buyout from a Giant Like Merck "A financial analysis of why Verona Pharma (VRNA) has become a prime acquisition target after its landmark FDA drug approval, and what a deal could mean."

One Year After FDA Approval, Is Verona Pharma the Next Big Pharma Acquisition?

#VeronaPharma #VRNA #Merck #Biotech #FDA #COPD #StockMarket #FactRage #FactRageNews

tglm.us/V3gtG

Merck to acquire Verona Pharma for $10 billion Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Click Subscribe #Merck #VeronaPharma #Acquisition #PharmaNews #Biotech

Merck shells out $10 billion for Verona in bid to diversify beyond Keytruda Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. drugmaker's respiratory treatments as part of efforts to reduce dependence on its blockbuster cancer treatment.

#Reuters #pharma #pharmaceuticals #healthcare #Merck #MSD #lungtherapy #respiratory #Verona #FT #VeronaPharma #lungdiseases #FinancialTimes #inhalable #nonsteroidtreatment #Ohtuvayre #patients #chronicobstructivepulmonarydisease #COPD #Ohtuvayretherapy
www.reuters.com/business/hea...

Is MSD preparing a $10bn deal to buy Verona? Reports suggest MSD is eyeing a $10bn takeover offer for respiratory drug specialist Verona Pharma and its fast-growing COPD therapy Ohtuvayre.

The pace of M&A in the #pharma sector this year looks set to accelerate even further, with reports emerging this morning that #MSD is readying a #takeover offer for respiratory medicine specialist #VeronaPharma.

pharmaphorum.com/news/msd-pre...

Merck nears $10 billion deal for respiratory drugmaker Verona, FT reports (Reuters) -Merck is nearing a roughly $10 billion deal to buy lung disease-focused biotech Verona Pharma (NASDAQ:VRNA), the Financial Times reported on Wednesday. Merck (NSE:PROR) would pay $107 per American depository share for Verona, the report said, citing three people familiar with the matter. Merck and Verona didn’t immediately respond to Reuters requests for comment. Reuters couldn’t immediately verify the report. Merck has relied on its best-seller Keytruda, which had nearly $30 billion in sales in 2024, to fuel its growth for years but the drug’s patents will begin to expire in 2028. In response to that, the company has embarked on a spree of deals to diversify revenue streams. Last month, FT reported that Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion. In March, Merck said that it has signed an up to $2 billion licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals. Verona is a biopharmaceutical company working on developing therapies for the treatment of chronic respiratory diseases. Its first commercial product, Ohtuvayre, is used in the treatment of COPD, a chronic lung condition. Verona reported total net revenue of $76.3 million in the first quarter of 2025.

Click Subscribe #Merck #VeronaPharma #Biotech #LungHealth #Pharmaceuticals